Hikal unveils High Potency API Lab at integrated Innovation Centre in Pune

Hikal Ltd., which caters to global life sciences companies, has announced the inauguration of its High Potency Active Pharmaceutical Ingredient (HPAPI) Laboratory at its Integrated Innovation Centre in Pune.

This facility will further strengthen its end-to-end CDMO capabilities and enhance its ability to safely develop and test, and deliver ‘highly potent compounds’ for the global pharmaceutical industry, it said. 

The new cGMP-compliant HPAPI Laboratory is equipped with isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements. 

The lab is purpose-built to support the development of complex oncology and speciality molecules, including components of Antibody Drug Conjugates (ADCs), Peptide Drug Conjugates (PDCs), and Proteolysis Targeting Chimeras (PROTACs), the company said.

“Our new HPAPI laboratory represents a critical step forward in expanding our capabilities and reinforcing our unwavering commitment to innovation, safety and customer excellence,” said Sameer Hiremath, Vice Chairman & Managing Director, Hikal Ltd.

“With this new addition to our technology toolbox, we are well-positioned to meet the growing demand for potent molecule development while maintaining the highest global standards of containment and compliance,” he added.